Nifty
Sensex
:
:
22957.10
75410.39
-10.55 (-0.05%)
-7.65 (-0.01%)

Pharmaceuticals & Drugs - API

Rating :
N/A

BSE: 530239 | NSE: SUVEN

99.70
24-May-2024
  • Open
  • High
  • Low
  • Previous Close
  •  98.00
  •  101.50
  •  97.60
  •  98.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  198969
  •  198.64
  •  129.00
  •  55.15

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,141.48
  • N/A
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,977.50
  • N/A
  • 7.93

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.57%
  • 2.27%
  • 22.30%
  • FII
  • DII
  • Others
  • 0.46%
  • 1.05%
  • 4.35%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -30.44
  • -45.66
  • 0.15

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 62.82
  • 9.46

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 37.69
  • 17.91

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.09
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.99
  • 10.34
  • 13.91

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.81
  • -6.54
  • -12.71

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
2.39
2.61
-8.43%
2.45
3.00
-18.33%
3.06
4.39
-30.30%
3.80
3.54
7.34%
Expenses
32.67
34.13
-4.28%
48.64
54.59
-10.90%
26.57
26.09
1.84%
31.81
24.62
29.20%
EBITDA
-30.29
-31.52
-
-46.19
-51.59
-
-23.51
-21.70
-
-28.01
-21.08
-
EBIDTM
-1,269.94%
-1,207.28%
-1,884.66%
-1,718.42%
-768.33%
-494.71%
-737.79%
-595.65%
Other Income
4.28
5.60
-23.57%
6.07
2.21
174.66%
5.14
0.21
2,347.62%
5.64
0.44
1,181.82%
Interest
0.03
0.05
-40.00%
0.03
0.06
-50.00%
0.04
0.07
-42.86%
0.05
0.10
-50.00%
Depreciation
1.51
1.67
-9.58%
1.60
1.67
-4.19%
1.73
1.62
6.79%
1.66
1.58
5.06%
PBT
-27.54
-27.65
-
-41.77
-51.12
-
-12.68
-23.18
-
-24.09
-16.33
-
Tax
-1.00
0.00
-
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PAT
-26.54
-27.65
-
-41.77
-51.12
-
-12.68
-23.18
-
-24.09
-16.33
-
PATM
-1,112.83%
-1,058.83%
-1,704.00%
-1,702.76%
-414.38%
-528.52%
-634.45%
-461.35%
EPS
-1.22
-1.27
-
-1.92
-2.34
-
-0.58
-1.47
-
-1.10
-1.03
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Net Sales
11.70
13.54
11.84
13.48
14.41
285.67
625.26
543.53
499.52
520.86
117.28
Net Sales Growth
-13.59%
14.36%
-12.17%
-6.45%
-94.96%
-54.31%
15.04%
8.81%
-4.10%
344.12%
 
Cost Of Goods Sold
0.01
0.00
0.00
0.00
0.00
68.74
152.17
147.06
162.64
177.61
44.18
Gross Profit
11.69
13.54
11.84
13.48
14.41
216.93
473.09
396.47
336.88
343.25
73.10
GP Margin
99.94%
100%
100%
100%
100%
75.94%
75.66%
72.94%
67.44%
65.90%
62.33%
Total Expenditure
139.69
139.18
134.09
93.42
130.13
296.65
423.61
414.46
398.18
361.40
104.61
Power & Fuel Cost
-
0.00
0.00
0.00
1.63
19.37
33.56
31.50
29.32
28.04
7.95
% Of Sales
-
0%
0%
0%
11.31%
6.78%
5.37%
5.80%
5.87%
5.38%
6.78%
Employee Cost
-
18.62
21.02
18.53
17.41
36.49
61.27
52.17
35.64
31.75
12.25
% Of Sales
-
137.52%
177.53%
137.46%
120.82%
12.77%
9.80%
9.60%
7.13%
6.10%
10.45%
Manufacturing Exp.
-
115.72
106.53
71.16
103.25
147.09
144.07
153.86
139.49
95.91
29.74
% Of Sales
-
854.65%
899.75%
527.89%
716.52%
51.49%
23.04%
28.31%
27.92%
18.41%
25.36%
General & Admin Exp.
-
4.50
6.09
3.31
4.96
13.48
20.66
19.45
22.48
20.14
8.38
% Of Sales
-
33.23%
51.44%
24.55%
34.42%
4.72%
3.30%
3.58%
4.50%
3.87%
7.15%
Selling & Distn. Exp.
-
0.00
0.00
0.00
0.00
4.89
8.57
7.46
6.73
5.17
2.06
% Of Sales
-
0%
0%
0%
0%
1.71%
1.37%
1.37%
1.35%
0.99%
1.76%
Miscellaneous Exp.
-
0.33
0.46
0.41
2.88
6.59
3.31
2.95
1.88
2.77
2.06
% Of Sales
-
2.44%
3.89%
3.04%
19.99%
2.31%
0.53%
0.54%
0.38%
0.53%
0.04%
EBITDA
-128.00
-125.64
-122.25
-79.94
-115.72
-10.98
201.65
129.07
101.34
159.46
12.67
EBITDA Margin
-1,094.02%
-927.92%
-1032.52%
-593.03%
-803.05%
-3.84%
32.25%
23.75%
20.29%
30.61%
10.80%
Other Income
21.13
8.45
1.60
7.75
14.04
27.25
23.27
21.09
19.62
8.58
3.18
Interest
0.15
0.54
0.67
0.94
0.55
1.91
4.63
5.68
5.88
4.71
5.06
Depreciation
6.50
6.54
4.39
4.35
4.17
14.20
24.76
21.41
17.50
11.78
4.44
PBT
-106.08
-124.27
-125.71
-77.47
-106.40
0.16
195.53
123.07
97.58
151.55
6.36
Tax
-1.00
0.00
0.00
-5.32
-12.18
24.06
71.84
35.88
25.74
42.80
-1.99
Tax Rate
0.94%
0.00%
0.00%
6.87%
11.45%
15037.50%
36.74%
29.15%
26.38%
28.24%
-31.29%
PAT
-105.08
-118.27
-122.00
-72.15
-94.22
-23.90
123.69
87.19
71.85
108.75
8.35
PAT before Minority Interest
-105.08
-118.27
-122.00
-72.15
-94.22
-23.90
123.69
87.19
71.85
108.75
8.35
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-898.12%
-873.49%
-1030.41%
-535.24%
-653.85%
-8.37%
19.78%
16.04%
14.38%
20.88%
7.12%
PAT Growth
0.00%
-
-
-
-
-
41.86%
21.35%
-33.93%
1,202.40%
 
EPS
-4.82
-5.42
-5.59
-3.31
-4.32
-1.10
5.67
4.00
3.29
4.99
0.38

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Shareholder's Funds
375.32
96.15
108.01
143.35
239.13
767.41
667.00
595.28
559.31
106.39
Share Capital
21.81
14.54
12.73
12.73
12.73
12.73
12.73
12.73
12.73
11.57
Total Reserves
353.51
81.61
58.36
130.62
226.40
754.68
654.27
582.56
546.59
94.82
Non-Current Liabilities
2.46
3.57
4.50
12.07
24.51
30.20
28.21
40.54
86.43
57.06
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.25
22.65
37.08
55.09
54.62
Unsecured Loans
0.00
0.00
0.39
1.08
1.78
1.98
3.29
4.56
6.36
0.00
Long Term Provisions
1.88
2.00
1.73
1.72
1.49
3.69
2.84
2.39
2.27
0.00
Current Liabilities
105.03
102.21
109.81
120.03
156.97
225.83
208.05
210.62
127.39
35.08
Trade Payables
1.66
1.99
3.00
5.78
7.09
56.82
37.94
35.60
43.89
20.14
Other Current Liabilities
8.44
5.44
12.13
20.00
32.00
29.43
46.14
48.18
42.45
0.63
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
30.57
30.49
24.16
28.24
0.00
Short Term Provisions
94.92
94.78
94.68
94.25
117.88
109.01
93.49
102.68
12.81
14.32
Total Liabilities
482.81
201.93
222.32
275.45
420.61
1,023.44
903.26
846.44
773.13
198.53
Net Block
37.21
37.56
20.96
24.69
22.35
307.73
305.72
305.35
171.95
109.77
Gross Block
89.43
83.40
66.95
77.11
39.48
375.68
348.92
325.15
290.52
141.20
Accumulated Depreciation
52.22
45.83
45.99
52.42
17.13
67.95
43.19
19.80
118.57
31.43
Non Current Assets
137.32
41.44
25.74
115.95
22.37
349.61
322.10
318.79
291.31
115.72
Capital Work in Progress
0.00
3.55
4.77
0.00
0.02
24.74
9.72
7.20
107.01
3.66
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.07
0.07
0.07
0.00
2.29
Long Term Loans & Adv.
0.11
0.33
0.00
91.25
0.00
16.86
6.39
6.16
10.89
0.00
Other Non Current Assets
100.00
0.00
0.00
0.00
0.00
0.20
0.20
0.00
1.46
0.00
Current Assets
345.48
160.49
196.58
159.50
398.24
673.83
581.16
527.66
476.98
82.79
Current Investments
46.34
45.16
0.09
0.05
222.93
278.73
300.89
0.05
0.04
0.00
Inventories
0.00
0.02
0.14
0.00
0.00
139.47
92.51
83.46
81.81
24.40
Sundry Debtors
0.81
1.30
1.76
2.27
2.64
61.54
45.83
53.56
40.17
35.59
Cash & Bank
184.28
5.52
46.65
15.09
0.69
28.22
9.17
241.40
279.69
3.04
Other Current Assets
114.05
8.71
6.69
1.37
171.98
165.88
132.76
149.18
75.28
19.77
Short Term Loans & Adv.
100.92
99.78
141.25
140.72
169.20
115.53
99.87
108.96
34.06
14.93
Net Current Assets
240.46
58.28
86.77
39.48
241.27
448.00
373.11
317.04
349.59
47.71
Total Assets
482.80
201.93
222.32
275.45
420.61
1,023.44
903.26
846.45
773.14
198.53

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 08
Mar 07
Cash From Operating Activity
-103.15
-127.54
-96.02
-134.57
-52.61
69.94
109.17
67.50
3.94
16.24
PBT
-118.27
-122.00
-77.47
-106.40
0.16
195.53
123.07
97.58
6.36
10.76
Adjustment
4.74
-1.09
-2.70
-8.26
-4.87
10.32
12.91
10.98
11.22
6.54
Changes in Working Capital
11.48
-3.93
-14.70
-17.13
-32.98
-92.37
7.90
-14.36
-12.96
0.46
Cash after chg. in Working capital
-102.05
-127.02
-94.88
-131.79
-37.70
113.47
143.88
94.20
4.63
17.75
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1.10
-0.52
-1.15
-2.78
-14.92
-43.54
-34.71
-26.70
-0.69
-1.51
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-260.65
-22.23
55.84
146.22
37.13
-0.61
-310.64
-38.63
-16.20
-20.46
Net Fixed Assets
-2.48
-15.23
5.39
-37.61
360.92
-41.78
-26.29
-187.49
-19.37
-21.18
Net Investments
-102.35
-130.73
-53.26
117.43
21.74
-15.06
-342.87
-14.91
2.67
-0.87
Others
-155.82
123.73
103.71
66.40
-345.53
56.23
58.52
163.77
0.50
1.59
Cash from Financing Activity
395.54
145.69
34.86
2.81
4.53
-52.07
-30.39
-68.07
5.52
12.62
Net Cash Inflow / Outflow
31.75
-4.07
-5.33
14.45
-10.94
17.26
-231.86
-39.20
-6.74
8.40
Opening Cash & Equivalents
5.27
9.35
14.68
0.23
17.89
8.69
240.55
279.75
9.78
1.37
Closing Cash & Equivalent
37.02
5.27
9.35
14.68
0.23
25.95
8.69
240.55
3.04
9.78

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Book Value (Rs.)
17.21
6.09
5.15
11.26
18.79
60.29
52.40
46.77
43.56
9.19
ROA
-34.54%
-57.51%
-28.99%
-27.07%
-3.31%
12.84%
9.97%
8.87%
22.38%
4.49%
ROE
-50.17%
-145.90%
-67.29%
-49.27%
-4.75%
17.25%
13.81%
12.50%
32.91%
8.04%
ROCE
-49.89%
-117.81%
-60.09%
-54.67%
0.40%
26.01%
18.19%
15.43%
37.93%
7.51%
Fixed Asset Turnover
0.16
0.16
0.19
0.25
1.38
1.73
1.62
1.63
2.42
0.92
Receivable days
28.38
47.15
54.60
62.22
41.00
31.34
33.32
34.19
26.51
78.68
Inventory Days
0.00
2.53
3.83
0.00
0.00
67.71
58.98
60.29
37.16
71.95
Payable days
0.00
0.00
0.00
18.53
39.04
38.79
33.17
35.72
32.74
57.23
Cash Conversion Cycle
28.38
49.67
58.43
43.70
1.96
60.26
59.13
58.77
30.93
93.40
Total Debt/Equity
0.00
0.01
0.02
0.01
0.01
0.04
0.11
0.14
0.20
0.51
Interest Cover
-218.91
-181.00
-81.35
-191.96
1.08
43.25
22.65
17.61
33.18
2.26

News Update:


  • Suven Pharmaceuticals to merge Cohance with itself
    1st Mar 2024, 11:30 AM

    Cohance is a leading CDMO and Merchant API platform with global leadership in select low-mid volume molecules as well as unique capabilities in the form of its antibody drug conjugates platform

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.